# Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

> **NCT00839306** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 240 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** Rabeprazole ER
- **DRUG:** Ranitidine

## Key facts

- **NCT ID:** NCT00839306
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-08
- **Final completion:** 2010-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839306, "Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00839306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*